Therapeutic Workshop
Neuro-Oncology: "Breaking Down the Barriers to New Neuro-Oncology Drugs"
Monday, February 11, 2008
9:30 AM
East Foyer
Brain cancers, particular glioblastoma multiforme, the most common and most aggressive, leave patients with a poor prognosis and limited treatment options. The standard of care includes invasive surgery and whole brain radiation, and even with this treatment, the survival rate for these patients remains very low. Beyond effectively killing brain cancer cells, another major challenge for drug developers is developing drugs that can successfully cross the blood-brain barrier in order to reach therapeutic concentrations. What companies are up to the challenge and are developing novel new targeted therapeutics and delivery technologies?
Moderators
- William Ho; Sr. Biotech Research Analyst, Bank of America Securities
Panelists
- E. Michael Egan; President and CEO, TransMolecular, Inc.
- Brad Thompson, Ph.D.; President and CEO, Oncolytics Biotech Inc.
- Thomas Davis, MD; CMO and VP Clinical Development, AVANT Immunotherapeutics
- Alan Ezrin, Ph.D.; President and CEO, Bradmer Pharmaceuticals
- Steven S. Rosenfeld, M.D., Ph.D.; Professor of Pathology, Neurology and Anatomy and Cell Biology, Columbia University Medical Center, and Chief, Division of Neuro-Oncology
Who's Who
Expert